1,221 results on '"Grever, Michael R."'
Search Results
2. Evaluation of bleeding events in patients receiving acalabrutinib therapy
3. Long-term outcomes in patients with relapsed or refractory hairy cell leukemia treated with vemurafenib monotherapy
4. Depth of response and progression-free survival in chronic lymphocytic leukemia patients treated with ibrutinib
5. The impact of increasing karyotypic complexity and evolution on survival in patients with CLL treated with ibrutinib
6. Correction: Evaluation of bleeding events in patients receiving acalabrutinib therapy
7. The long noncoding RNA, treRNA, decreases DNA damage and is associated with poor response to chemotherapy in chronic lymphocytic leukemia
8. Phase 2 study of ibrutinib in classic and variant hairy cell leukemia
9. Incidence, description, and timing of serious and opportunistic infections in patients with hairy cell leukemia.
10. Clinical Development of 2′-Deoxycoformycin
11. Second cancer incidence in CLL patients receiving BTK inhibitors
12. Externally validated predictive clinical model for untreated del(17p13.1) chronic lymphocytic leukemia patients
13. Final results of EFC6663: A multicenter, international, phase 2 study of alvocidib for patients with fludarabine-refractory chronic lymphocytic leukemia
14. BRAFV600E accelerates disease progression and enhances immune suppression in a mouse model of B-cell leukemia
15. Near-tetraploidy is associated with Richter transformation in chronic lymphocytic leukemia patients receiving ibrutinib
16. Consensus guidelines for the diagnosis and management of patients with classic hairy cell leukemia
17. Herpes Zoster and Lymphopenia Associated with Sodium Stibogluconate Therapy for Cutaneous Leishmaniasis
18. Single‐center study of outcomes of patients with hairy cell leukemia who contracted SARS‐CoV‐2
19. Pharmaceutical Prospecting and the Potential for Pharmaceutical Crops. Natural Product Drug Discovery and Development at the United States National Cancer Institute
20. Historical overview of hairy cell leukemia
21. BRAFV600E induces ABCB1/P-glycoprotein expression and drug resistance in B-cells via AP-1 activation
22. Safety and activity of BTK inhibitor ibrutinib combined with ofatumumab in chronic lymphocytic leukemia: a phase 1b/2 study
23. Supplementary table 1 from A Phase I Trial of Single-Agent Reolysin in Patients with Relapsed Multiple Myeloma
24. Supplementary Tables 1-2 from A Pharmacokinetic/Pharmacodynamic Model of Tumor Lysis Syndrome in Chronic Lymphocytic Leukemia Patients Treated with Flavopiridol
25. Supplementary table 2 from A Phase I Trial of Single-Agent Reolysin in Patients with Relapsed Multiple Myeloma
26. supplemental legend from A Phase I Trial of Single-Agent Reolysin in Patients with Relapsed Multiple Myeloma
27. Supplementary Figure Legends from A Pharmacokinetic/Pharmacodynamic Model of Tumor Lysis Syndrome in Chronic Lymphocytic Leukemia Patients Treated with Flavopiridol
28. Supplementary Figures 1-7 from A Pharmacokinetic/Pharmacodynamic Model of Tumor Lysis Syndrome in Chronic Lymphocytic Leukemia Patients Treated with Flavopiridol
29. Supplementary figure 1 from A Phase I Trial of Single-Agent Reolysin in Patients with Relapsed Multiple Myeloma
30. Two-inhibitor salvage therapy for hairy cell leukemia
31. Hairy cell leukemia: Update on molecular profiling and therapeutic advances
32. Validation of ZAP-70 methylation and its relative significance in predicting outcome in chronic lymphocytic leukemia
33. A phase 1 clinical trial of flavopiridol consolidation in chronic lymphocytic leukemia patients following chemoimmunotherapy
34. FISH Analysis of CDKN2A/B Deletion in Chronic Lymphocytic Leukemia
35. Retrospective Analysis of Residual Hairy Cell Leukemia Measured By IHC or Flow Cytometry and Frontline Treatment with Pentostatin on Time to Next Treatment
36. Treatment of CLL-Associated Autoimmune Cytopenias and Outcomes in a Single Institution Cohort Study
37. Incidence, Description, and Timing of Serious or Opportunistic Infections in Patients with Hairy Cell Leukemia Treated with Purine Nucleoside Analogues
38. Characterizing the Development of Secondary Myelodysplastic Syndrome (MDS) with Antecedent or Concurrent Chronic Lymphocytic Leukemia (CLL) in the Era of Small Molecule Inhibitors for the Treatment of CLL
39. Extended Follow up of a Phase 2 Study of Ibrutinib in Hairy Cell Leukemia
40. Patient characteristics that predict Richter's transformation in patients with chronic lymphocytic leukemia treated with ibrutinib
41. Cyclophosphamide, alvocidib (flavopiridol), and rituximab, a novel feasible chemoimmunotherapy regimen for patients with high-risk chronic lymphocytic leukemia
42. Combined BCL2 and BTK inhibition in CLL demonstrates efficacy after monotherapy with both classes
43. Genome-wide methylation profiling in decitabine-treated patients with acute myeloid leukemia
44. ER stress and autophagy: new discoveries in the mechanism of action and drug resistance of the cyclin-dependent kinase inhibitor flavopiridol
45. Clinical and pharmacodynamic activity of bortezomib and decitabine in acute myeloid leukemia
46. Clinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabine
47. Impact of sex on outcomes in patients with hairy cell leukemia (HCL): An HCL Patient Data Registry (PDR) analysis.
48. Racial and socioeconomic disparities among patients with chronic lymphocytic leukemia: Analysis of Surveillance, Epidemiology, and End Results program data.
49. Sorbicillinoid analogs with cytotoxic and selective anti-Aspergillus activities from Scytalidium album
50. The Role of Plants in the Drug Discovery Program of the United States National Cancer Institute
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.